Use of aldosterone antagonists in resistant hypertension

被引:36
作者
Calhoun, David A. [1 ]
机构
[1] Univ Alabama Birmingham, Vasc Biol & Hypertens Program, Birmingham, AL USA
关键词
D O I
10.1016/j.pcad.2006.02.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Resistant hypertension is defined as an elevated blood pressure in spite of treatment with 3 different anti hypertensive agents. The prevalence of resistant hypertension is unknown, but recent cross-sectional analyses and hypertension outcome studies suggest it is a common clinical problem and will become even more so with an aging and increasingly heavy population. Secondary causes of hypertension are common in patients with resistant hypertension, in particular, obstructive sleep apnea and hyperalclosteronism. Treatment of resistant hypertension is predicated upon identification and reversal of secondary causes of hypertension, as possible, and effective use of multidrug regimens. Recent clinical studies indicate that alclosterone antagonists, spironolactone and amiloride, provide significant additional blood pressure reduction when added to treatment regimens of patients with resistant hypertension. Both agents are generally well tolerated. Hyperkalemia is an uncommon complication of alclosterone antagonists, but it can occur; therefore, biochemical monitoring is necessary, particularly in high-risk patients. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:387 / 396
页数:10
相关论文
共 34 条
[1]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[2]   Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea [J].
Becker, HF ;
Jerrentrup, A ;
Ploch, T ;
Grote, L ;
Penzel, T ;
Sullivan, CE ;
Peter, JH .
CIRCULATION, 2003, 107 (01) :68-73
[3]   Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled [J].
Bramlage, P ;
Pittrow, D ;
Wittchen, HU ;
Kirch, W ;
Boehler, S ;
Lehnert, H ;
Hoefler, M ;
Unger, T ;
Sharma, AM .
AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (10) :904-910
[4]   Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea [J].
Calhoun, DA ;
Nishizaka, MK ;
Zaman, MA ;
Harding, SM .
CHEST, 2004, 125 (01) :112-117
[5]   Hyperaldosteronism among with resistant black and white subjects hypertension [J].
Calhoun, DA ;
Nishizaka, MK ;
Zaman, MA ;
Thakkar, RB ;
Weissmann, P .
HYPERTENSION, 2002, 40 (06) :892-896
[6]  
Cushman William C, 2002, J Clin Hypertens (Greenwich), V4, P393
[7]   Low-renin status in therapy-resistent hypertension: a clue to efficient treatment [J].
Eide, IK ;
Torjesen, PA ;
Drolsum, A ;
Babovic, A ;
Lilledahl, NP .
JOURNAL OF HYPERTENSION, 2004, 22 (11) :2217-2226
[8]   Efficacy and tolerability of eplerenone and losartan in hypertensive of eplerenone and black and white patients [J].
Flack, JM ;
Oparil, S ;
Pratt, JH ;
Roniker, B ;
Garthwaite, S ;
Kleiman, JH ;
Yang, YH ;
Krause, SL ;
Workman, D ;
Saunders, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (07) :1148-1155
[9]   Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio [J].
Gallay, BJ ;
Ahmad, S ;
Xu, L ;
Toivola, B ;
Davidson, RC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (04) :699-705
[10]   Resistant hypertension revisited: A comparison of two university-based cohorts [J].
Garg, JP ;
Elliott, WJ ;
Folker, A ;
Izhar, M ;
Black, HR .
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) :619-626